Trusz-Gluza M, Giec L, Dabrowski A, Kuch J, Piwowarska W, Pracka H, Sadowski Z, Wodniecki J, Filipecki A, Szydło K
I Kliniki Kardiologii IK Sl. AM Katowicach.
Kardiol Pol. 1992 May;36(5):280-3.
Study was undertaken to assess whether proarrhythmic response to antiarrhythmic drug is a risk factor for cardiac death in patients (pts) with ischaemic heart disease (IHD). In 782 pts with IHD and frequent and/or complex ventricular ectopic beats (VEB) 1041 drug tests guided by 24 hour Holter monitoring were conducted. The following drugs were assessed: propranolol, disopyramide, mexiletine, amiodarone. Pro-arrhythmia was defined according to Velebit: 1/greater than or equal to 4-fold increase in VEBs, 2/greater than or equal to 10-fold increase in repetitive forms of 3/new occurrence of ventricular tachycardia or ventricular fibrillation (VT/VF). Proarrhythmic effect was observed in 8.4% of pts and in 7.9% of drug tests. The frequency with individual drugs ranged from 5.7% to 9%. No drug was completely free of this type of reaction. Antiarrhythmic drugs inducing arrhythmogenic response were eliminated. Pts were followed-up for a mean of 22 months (range 1-49). Chronic antiarrhythmic treatment was conducted. Pts were discharged taking the agent deemed most effective for suppression of arrhythmia. Follow-up visits were made every 6-12 months. All cases of death were verified. In long-term observation cardiac death and sudden death occurred in 53 and 32 pts. With actuarial analysis (Kaplan-Meler method, log rank test) there was significant difference in cardiac death (p less than 0.05) of pro-arrhythmia (+) compared with ++pro-arrhythmia (-) pts at yr (11% v 4%, 7% v 3%) and 3 yr (24% x 11%, 16% v 7%). The relative importance of baseline clinical variables in predicting survival was assessed with a stepwise Cox regression.(ABSTRACT TRUNCATED AT 250 WORDS)
开展本研究以评估抗心律失常药物的促心律失常反应是否为缺血性心脏病(IHD)患者心脏死亡的危险因素。对782例患有IHD且有频发和/或复杂室性早搏(VEB)的患者进行了1041次在24小时动态心电图监测指导下的药物试验。评估了以下药物:普萘洛尔、丙吡胺、美西律、胺碘酮。根据韦莱比特的标准定义促心律失常:1/室性早搏增加大于或等于4倍,2/重复性形式增加大于或等于10倍,3/新出现室性心动过速或心室颤动(VT/VF)。在8.4%的患者和7.9%的药物试验中观察到促心律失常作用。各药物的发生率在5.7%至9%之间。没有一种药物完全没有这种类型的反应。诱发致心律失常反应的抗心律失常药物被停用。对患者平均随访22个月(范围1 - 49个月)。进行了慢性抗心律失常治疗。患者出院时服用被认为对抑制心律失常最有效的药物。每6 - 12个月进行随访。所有死亡病例均得到核实。在长期观察中,53例患者发生心脏死亡,32例患者发生猝死。通过精算分析(Kaplan - Meier法,对数秩检验),促心律失常(+)患者与促心律失常( - )患者在1年(11%对4%,7%对3%)和3年(24%对11%,16%对7%)时的心脏死亡有显著差异(p小于0.05)。通过逐步Cox回归评估基线临床变量在预测生存方面的相对重要性。(摘要截断于250字)